Short answer
PTC THERAPEUTICS, INC. (PTCT) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $273M (down 76.8% year over year) with net income of −$3M.
Q1 2026 key financials · XBRL
- Revenue
- $273M
- −76.8% YoY
- Net income
- −$3M
- −100.3% YoY
- Operating margin
- 16.5%
- EPS (diluted)
- −$0.03
- −100.3% YoY
Source: XBRL data from the PTC THERAPEUTICS, INC. (PTCT) Q1 2026 10-Q on SEC EDGAR. USD.
PTC THERAPEUTICS, INC. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Cash, equivalents and marketable securities $1.89B as of March 31, 2026
- Operating cash flow $(59.0)M vs $870.1M YoY, reflecting clinical development and commercial spending
- Investing cash outflow $(93.7)M vs $(184.4)M YoY, primarily marketable-securities and fixed-asset purchases
- Novartis upfront payment $1.0B received January 2025; potential milestones up to $1.9B
- Vatiquinone open-label study planned for Q3 2026 following FDA feedback on NDA resubmission
Risk Factors
- No risk-factors section provided; excerpt contains Item 5 trading arrangements and exhibits only
- Insider-trading compliance risk; directors and officers must follow applicable federal securities laws
- Equity-sale activity; arrangements cover up to 52,963 shares through March 31, 2027
- Disclosure risk; Rule 10b5-1 plans adopted by three insiders and terminated by one director during the quarter
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other PTC THERAPEUTICS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.